Cytokinetics director sells 1,000 shares at $74.66
A Cytokinetics director sold 1,000 shares under a Rule 10b5-1 plan, leaving a direct holding of 9,184 shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
CYTOKINETICS INC (CYTK) reports that director Robert E. Landry sold 1,000 shares of common stock on September 11, 2026 in a transaction described as a sale in the open market or a private transaction at $74.66 per share. Following this sale, he directly holds 9,184 shares of Cytokinetics common stock. The transaction is affirmed as having been made under a Rule 10b5-1 trading plan, indicating it was executed according to a pre-established arrangement.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,000 | $74.66 | $75K |
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
open market or private transaction market
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CYTK report for Robert E. Landry?
Was the September 11, 2026 CYTK insider sale under a Rule 10b5-1 plan?
How many insider sell transactions did CYTK report in this Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.